11759645

Source:http://linkedlifedata.com/resource/pubmed/id/11759645

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0008976, umls-concept:C0034656, umls-concept:C0216784, umls-concept:C0264716
pubmed:issue	23
pubmed:dateCreated	2001-11-19
pubmed:abstractText	Actions of angiotensin II may contribute to the progression of heart failure despite treatment with currently recommended drugs. We therefore evaluated the long-term effects of the addition of the angiotensin-receptor blocker valsartan to standard therapy for heart failure.
pubmed:commentsCorrections	http://linkedlifedata.com/resource/pubmed/commentcorrection/11759645-11948282, http://linkedlifedata.com/resource/pubmed/commentcorrection/11759645-11951861, http://linkedlifedata.com/resource/pubmed/commentcorrection/11759645-11951862, http://linkedlifedata.com/resource/pubmed/commentcorrection/11759645-11951863, http://linkedlifedata.com/resource/pubmed/commentcorrection/11759645-12016625, http://linkedlifedata.com/resource/pubmed/commentcorrection/11759645-12439444
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/0255562
pubmed:citationSubset	AIM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Adrenergic beta-Antagonists, http://linkedlifedata.com/resource/pubmed/chemical/Angiotensin Receptor Antagonists, http://linkedlifedata.com/resource/pubmed/chemical/Angiotensin-Converting Enzyme..., http://linkedlifedata.com/resource/pubmed/chemical/Tetrazoles, http://linkedlifedata.com/resource/pubmed/chemical/Valine, http://linkedlifedata.com/resource/pubmed/chemical/valsartan
pubmed:status	MEDLINE
pubmed:month	Dec
pubmed:issn	0028-4793
pubmed:author	pubmed-author:CohnJ NJN, pubmed-author:TognoniGG, pubmed-author:Valsartan Heart Failure Trial Investigators
pubmed:issnType	Print
pubmed:day	6
pubmed:volume	345
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	1667-75
pubmed:dateRevised	2010-11-18
pubmed:meshHeading	pubmed-meshheading:11759645-Adrenergic beta-Antagonists, pubmed-meshheading:11759645-Angiotensin Receptor Antagonists, pubmed-meshheading:11759645-Angiotensin-Converting Enzyme Inhibitors, pubmed-meshheading:11759645-Chronic Disease, pubmed-meshheading:11759645-Double-Blind Method, pubmed-meshheading:11759645-Drug Therapy, Combination, pubmed-meshheading:11759645-Female, pubmed-meshheading:11759645-Heart Failure, pubmed-meshheading:11759645-Hospitalization, pubmed-meshheading:11759645-Humans, pubmed-meshheading:11759645-Male, pubmed-meshheading:11759645-Middle Aged, pubmed-meshheading:11759645-Probability, pubmed-meshheading:11759645-Quality of Life, pubmed-meshheading:11759645-Stroke Volume, pubmed-meshheading:11759645-Survival Analysis, pubmed-meshheading:11759645-Tetrazoles, pubmed-meshheading:11759645-Valine
pubmed:year	2001
pubmed:articleTitle	A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
pubmed:affiliation	Department of Medicine, University of Minnesota Medical School, Minneapolis, 55455, USA.
pubmed:publicationType	Journal Article, Clinical Trial, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study